ASND
Income statement / Annual
Last year (2024), Ascendis Pharma A/S's total revenue was $363.64 M,
an increase of 36.34% from the previous year.
In 2024, Ascendis Pharma A/S's net income was -$378.08 M.
See Ascendis Pharma A/S,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$363.64 M |
$266.72 M |
$51.17 M |
$7.78 M |
$6.95 M |
$13.38 M |
$10.58 M |
$1.53 M |
$4.61 M |
$8.12 M |
| Cost of Revenue |
$44.26 M
|
$44.40 M
|
$12.14 M
|
$3.52 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$319.38 M
|
$222.32 M
|
$39.04 M
|
$4.26 M
|
$6.95 M
|
$13.38 M
|
$10.58 M
|
$1.53 M
|
$4.61 M
|
$8.12 M
|
| Gross Profit Ratio |
0.88
|
0.83
|
0.76
|
0.55
|
1
|
1
|
1
|
1
|
1
|
1
|
| Research and Development Expenses |
$307.00 M
|
$413.45 M
|
$379.62 M
|
$295.87 M
|
$260.90 M
|
$191.62 M
|
$140.28 M
|
$99.59 M
|
$66.02 M
|
$40.53 M
|
| General & Administrative Expenses |
$284.55 M
|
$258.79 M
|
$0.00
|
$0.00
|
$0.00
|
$48.47 M
|
$25.06 M
|
$13.48 M
|
$11.50 M
|
$9.42 M
|
| Selling & Marketing Expenses |
$0.00
|
$5.62 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$284.55 M
|
$264.41 M
|
$221.23 M
|
$160.18 M
|
$76.67 M
|
$48.47 M
|
$25.06 M
|
$13.48 M
|
$11.50 M
|
$9.42 M
|
| Other Expenses |
$6.60 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$0.00
|
| Operating Expenses |
$598.15 M
|
$677.86 M
|
$600.85 M
|
$456.05 M
|
$337.57 M
|
$240.09 M
|
$165.34 M
|
$113.07 M
|
$77.53 M
|
$49.94 M
|
| Cost And Expenses |
$642.40 M
|
$722.26 M
|
$612.99 M
|
$459.57 M
|
$337.57 M
|
$240.09 M
|
$165.34 M
|
$113.07 M
|
$77.53 M
|
$49.94 M
|
| Interest Income |
$14.36 M
|
$16.86 M
|
$52.18 M
|
$692,000.00
|
$1.81 M
|
$17.80 M
|
$4.02 M
|
$923,000.00
|
$123,000.00
|
$13,000.00
|
| Interest Expense |
$65.50 M
|
$44.07 M
|
$50.49 M
|
$3.91 M
|
$1.92 M
|
$1.22 M
|
$127,000.00
|
$97,000.00
|
$5,000.00
|
$6,000.00
|
| Depreciation & Amortization |
$17.71 M
|
$18.91 M
|
$17.63 M
|
$16.00 M
|
$8.80 M
|
$6.67 M
|
$908,175.00
|
$689,460.00
|
$710,022.00
|
$558,000.00
|
| EBITDA |
-$290.02 M |
-$411.17 M |
-$556.04 M |
-$423.67 M |
-$328.88 M |
-$217.03 M |
-$150.18 M |
-$109.88 M |
-$72.12 M |
-$33.01 M |
| EBITDA Ratio |
-0.8
|
-1.54
|
-10.3
|
-54.47
|
-47.3
|
-16.23
|
-14.19
|
-71.82
|
-15.66
|
-5.08
|
| Operating Income Ratio |
-0.77
|
-1.71
|
-10.98
|
-58.09
|
-47.55
|
-16.95
|
-14.63
|
-72.9
|
-15.83
|
-5.15
|
| Total Other Income/Expenses Net |
-$94.48 M
|
-$18.60 M
|
-$16.00 M
|
$67.85 M
|
-$88.55 M
|
$8.47 M
|
$24.27 M
|
-$12.83 M
|
$4.19 M
|
$8.25 M
|
| Income Before Tax |
-$373.24 M
|
-$474.14 M
|
-$577.82 M
|
-$383.94 M
|
-$419.17 M
|
-$218.25 M
|
-$130.49 M
|
-$124.37 M
|
-$68.73 M
|
-$33.57 M
|
| Income Before Tax Ratio |
-1.03
|
-1.78
|
-11.29
|
-49.36
|
-60.29
|
-16.32
|
-12.33
|
-81.29
|
-14.92
|
-4.14
|
| Income Tax Expense |
$4.84 M
|
$7.30 M
|
$5.38 M
|
-$367,000.00
|
-$219,000.00
|
-$234,000.00
|
-$394,000.00
|
-$477,000.00
|
-$227,000.00
|
-$652,000.00
|
| Net Income |
-$378.08 M
|
-$481.45 M
|
-$583.19 M
|
-$383.58 M
|
-$418.96 M
|
-$218.02 M
|
-$130.10 M
|
-$123.90 M
|
-$68.51 M
|
-$32.92 M
|
| Net Income Ratio |
-1.04
|
-1.81
|
-11.4
|
-49.32
|
-60.26
|
-16.3
|
-12.3
|
-80.98
|
-14.87
|
-4.06
|
| EPS |
-6.59 |
-8.55 |
-10.4 |
-7 |
-8.28 |
-4.69 |
-3.17 |
-3.68 |
-2.58 |
-1.39 |
| EPS Diluted |
-6.59 |
-8.55 |
-10.4 |
-7 |
-8.28 |
-4.69 |
-3.17 |
-3.68 |
-2.58 |
-1.39 |
| Weighted Average Shares Out |
$57.35 M
|
$56.29 M
|
$56.07 M
|
$54.77 M
|
$50.62 M
|
$46.51 M
|
$41.09 M
|
$33.63 M
|
$26.56 M
|
$23.68 M
|
| Weighted Average Shares Out Diluted |
$57.35 M
|
$56.29 M
|
$56.07 M
|
$54.77 M
|
$50.62 M
|
$46.51 M
|
$41.09 M
|
$33.63 M
|
$26.56 M
|
$23.77 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
